CD19 CAR-T cell therapy (Miltenyi Biomedicine)

N/A

Report date: 2025/06/26 20:00:07

Base Information

Drug NameCD19 CAR-T cell therapy (Miltenyi Biomedicine)

Drug Alias NamehuCAR19

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMiltenyi Biomedicine Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi Biomedicine Gmbh

Inactive CompaniesN/A

Active IndicationsLymphomaLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A